Biocompatible Micro Tweezers for 3D Hydrogel Organoid Array Mechanical Characterization

Researchers presented novel biocompatible Polydimethylsiloxane-based micromechanical tweezers capable of the stiffness characterization and manipulation of hydrogel-based organoids.
[PLoS One]
[zotpress userid=” items=’BBBBBBBB’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Single-Cell Analysis of Somatic Mutation Burden in Mammary Epithelial Cells of Pathogenic BRCA1/2 Mutation Carriers

Investigators used an accurate, single-cell whole genome sequencing approach to first show that telomerized primary mammary epithelial cells heterozygous for a highly penetrant BRCA1 variant displayed a robustly elevated mutation frequency as compared to their isogenic control cells.
[Journal of Clinical Investigation]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

Fate Therapeutics Announces FDA Clearance for FT536, a First-in-Class MICA/B-targeted CAR NK Cell Product Candidate for the Treatment of Solid Tumors

Fate Therapeutics, Inc. announced that the US FDA has cleared the company’s Investigational New Drug application for FT536, an off-the-shelf, multiplexed-engineered, iPSC-derived, chimeric antigen receptor NK cell product candidate.
[Fate Therapeutics, Inc.]
[zotpress userid=’7992332′ items=’CCCCCCCC’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

BioAtla Announces Clinical Collaboration with Bristol Myers Squibb to Study Mecbotamab Vedotin (BA3011) and Ozuriftamab Vedotin (BA3021) in Combination with Opdivo® (Nivolumab) for Treatment of Solid Tumors

BioAtla, Inc. announced that it has entered into a clinical collaboration with Bristol Myers Squibb to investigate BioAtla’s two lead CAB-ADC candidates, BA3011 and BA3021, in combination with Bristol Myers Squibb’s anti-PD-1 therapy nivolumab.
[BioAtla, Inc. (PR Newswire, Inc.)]
[zotpress userid=’7992332′ items=’BBBBBBBB’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

Human iPSC-Derived Fallopian Tube Organoids with BRCA1 Mutation Recapitulate Early-Stage Carcinogenesis

Researchers generated human fallopian tube epithelial (FTE) organoids from BRCA1 mutation carriers that provided a faithful physiological in vitro model of FTE lesion generation and early carcinogenesis.
[Cell Reports]
[zotpress userid=’7992332′ items=’BBBBBBBB’ style=’apa’ cite=’yes’]
Full ArticleGraphical Abstract
Bookmark

No account yet? Register

Share

SOTIO Announces Clinical Collaboration with MSD to Evaluate IL-15 Superagonist, SOT101, in Combination with KEYTRUDA® (Pembrolizumab) in Patients with Solid Tumors

SOTIO Biotech announced that it has entered into a clinical trial collaboration and supply agreement with MSD to evaluate the combination of SOT101, SOTIO’s IL-15 superagonist, and MSD’s KEYTRUDA® in patients with selected advanced/refractory solid tumors in the Phase II AURELIO-04 study.
[SOTIO Biotech]
[zotpress userid=’7992332′ items=’nan’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

The SETDB1–TRIM28 Complex Suppresses Antitumor Immunity

An epigenetic CRISPR-Cas9 screen of 1,218 chromatin regulators identified TRIM28 as a suppressor of PD-L1 expression.
[Cancer Immunology Research]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

Mesenchymal Stem Cell Therapy in Decompensated Liver Cirrhosis: A Long-Term Follow-Up Analysis of the Randomized Controlled Clinical Trial

Therapy of umbilical cord-derived MSC was not only well tolerated, but also significantly improved long-term survival rate, as well as the liver function in patients with Hepatits B Virus-related decompensated liver cirrhosis.
[Hepatology International]
[zotpress userid=’7992332′ items=’BBBBBBBB’ style=’apa’ cite=’yes’]
Full ArticleGraphical Abstract
Bookmark

No account yet? Register

Share

Three Researchers Honoured for Groundbreaking Work on Ovarian Cancer, Stem Cells and Blood Transfusions

Each year, the Ottawa Hospital honours three outstanding researchers for discoveries that are having an impact around the world. This year’s honourees have led game-changing discoveries and clinical trials in areas such as ovarian cancer, stem cells and blood transfusions.
[Ottawa Citizen]
[zotpress userid=’7992332′ items=’CCCCCCCC’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

B7-H3 Suppresses Anti-Tumor Immunity via the CCL2-CCR2-M2 Macrophage Axis and Contributes to Ovarian Cancer Progression

Transcriptome analysis revealed that B7-H3 was highly expressed in PD-L1-low, non-immunoreactive high-grade serous ovarian cancer tumors, and its expression negatively correlated with an IFNγ signature, which reflected the tumor immune-reactivity.
[Cancer Immunology Research]
[zotpress userid=” items=’6G9R4IKZ’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

Oncolytic Adenovirus Inhibits Malignant Ascites of Advanced Ovarian Cancer via Reprograming Ascitic Immune Microenvironment

Scientists found that oncolytic adenovirus conferred an effective ability to reduce ascites development and prolong overall survival.
[Molecular Therapy-Oncolytics]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
AbstractPress ReleaseGraphical Abstract
Bookmark

No account yet? Register

Share
Share